Of the 30 companies, three saw their stock prices increase, 26 saw their share prices decline, and one company's share price remained virtually flat month over month.

The ruling prevents the FDA rule on LDTs, which is opposed by much of the clinical lab industry and many segments of the broader healthcare industry, from going into effect.

The firm's Innovance Antithrombin assay is used to monitor antithrombin activity levels in hemophilia patients and aid dosing decisions for a routine prophylaxis.

The automated DxC 500 I analyzer has a throughput of up to 800 clinical chemistry tests and 100 immunoassays per hour.

Last week, readers were most interested in a story about the potentially devastating effects that cuts in US funding for tuberculosis may effect.

NEW YORK — Tasso has struck a deal to offer its blood-collection devices in Japan through a new joint venture with Tokyo-based drug development services provider Shin Nippon Biomedical Laboratories, ...

The company presented its results this week at a conference and anticipates that with additional validation early next year, it will be ready to file for regulatory approval.

NEW YORK – Invivoscribe announced Thursday that its test for FLT3 mutations in patients with leukemia has achieved regulatory compliance in the UK and Switzerland.

OptraScan has appointed Stephen Jones as its director of business development for Europe. Jones previously held sales and marketing positions at Agilent Technologies and Dako Denmark. The firm has ...